Navigation Links
10 Million Square Feet of Turf Set to be Treated in 2008 in Response to MRSA Outbreaks Nationwide
Date:1/8/2008

ROCHESTER HILLS, Mich., Jan. 8 /PRNewswire/ -- CSG/SportsCoatings, today announced approximately 10 million square feet of synthetic turf will be treated with its industry-leading antimicrobial coating, TurfAide(TM), in 2008 -- up from 1.5 million square feet in 2007.

The exponential increase in demand for TurfAide has been attributed to several factors, including a 2007 report in the Journal of the American Medical Association that found MRSA (methicillin-resistant Staphlycoccus aureas) is responsible for more than 94,000 serious infections and nearly 19,000 deaths each year. MRSA, a potentially deadly skin infection, is caused by staph bacteria that can survive on surfaces for days. The antimicrobial technology in TurfAide is proven to inhibit the growth of bacteria, fungi and mold for years with just one application.

According to three studies conducted by the Texas Department of State Health Services, the MRSA infection rate among football players is 16 times higher than the average person. Texas has synthetic turf at 18 percent of its high school fields.

"Schools, professional teams and recreation centers are recognizing the growing threat of sports-related infections," said CSG/SportsCoatings CEO Craig Andrews. "More synthetic turf systems will be treated with TurfAide than all other antimicrobial products combined in 2008; because it's a proven and powerful technology that's been safely used in medical and consumer goods for over 30 years."

"With bacterial infections like MRSA and fungi like ringworm affecting many student athletes across the country, the need to protect your facilities has become a necessity," said Jim Weaver, Virginia Tech University Athletics Director.

Virginia Tech University is one of many major Division I programs, National Football League franchises and high schools that have had their synthetic turf fields treated with TurfAide in the past 18 months. A small sampling of TurfAide clients includes: the NFL's New England Patriots, Minnesota Vikings, Cleveland Browns; the University of South Carolina and University of Tulsa; and the entire Plano Intermediate School District in Texas.

TurfAide made headlines in 2007 when the exclusive provider of AstroTurf(R) USA, General Sports Venue, made the choice to treat all of its turf systems with TurfAide at the factory level beginning in 2008.

"With infections such as staph and MRSA on the rise in the sports community, we are committed to providing the best defense available," said Michael Dennis, chairman of GSV.

Visit http://www.csgsportscoatings.com to find out more about the technology used in TurfAide.


'/>"/>
SOURCE CSG/SportsCoatings
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Laboratories Raises $18 Million in Institutional Financing
2. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
3. NeuroVasx, Inc. Announces $8.5 Million Private Placement and Completion of cPAX Aneurysm Treatment Study
4. Five Clinical Studies to Receive $2.5 Million Under Foundations 2007 Clinical Discovery Program
5. Female Health Company Receives Brazilian Order: Four Million FC Female Condoms
6. Immtech Receives $5.1 Million to Further African Sleeping Sickness Clinical Trials
7. Coley Pharmaceutical Group Receives $3.0 Million Milestone Payment from GlaxoSmithKline
8. Paratek Pharmaceuticals Announces the Close of $40 Million Private Placement to Finance Programs to Combat MRSA Infections
9. 38.7 Million People Break Guinness World Record for Stand Up Speak Out on International Day for the Eradication of Poverty
10. National Jewish, Brigham and Womens Awarded $37 Million to Identify Genes and Other Risk Factors that Influence the Development of COPD
11. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology:
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):